In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Morgan Stanley analyst Thibault Boutherin initiated coverage of Novartis (NVS) with an Underweight rating and CHF 91 price target The company ...